Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AG brings on new roaster end of 2017 and has sights on 20 million Oz over next 3-5 years ! http://www.foxbusiness.com/markets/2017/01/10/these-were-first-majestic-silver-corp-2-best-moves-2016.html
AG Jan 2019 $10 calls @ $1.10 look fantastic!
Expecting great return on my investment within 6 months !
NEW INVESTOR TAKES 25% STAKE JULY 18TH , 2017 AFTER EVALUATING COMPANY! FORM 13G HERE : http://www.nasdaq.com/symbol/dcix/sec-filings
13G dated July 18th showing major investor for 25% stake ! http://www.nasdaq.com/symbol/dcix/sec-filings
NOT JUST YES BUT HELL YES : http://nypost.com/2017/07/25/longtime-hockey-exec-rebrands-himself-as-activist-investor/
Form 6K stating a restructure by eliminating 25 German employees by year end to enhance the company financials!
$100,000 a pop and stolen in 2 minutes ! Sounds like a great investment with possible 300 million float ! DID I HEAR AEROSMITH SINGING "DOWN IN AN ELEVATOR " ?
Still no volume after 8:00 all you buyers
Where is the volume all you buyers ?
Buy 30 and get 30 stolen for the technology inside !
Good luck in buying a stock with an overbought RSI ! Too each their own !
Too each their own
When it hits .14 I will buy , until then I will be short !
WILL BE SHORTING
IMO Monday = .14
Go to Vegas and put your money in the slots
Another DCTH !
OVERBOUGHT BIG TIME !
All you stock knowledgeable people read the RSI !
43.8 million shares after a 1 : 500 reverse split in March 2015 ! OH BOY !
Charts show extremely overbought with the pumping going on , look for a substantial pullback Monday !
Forward looking news is priced in Already! Maybe they will announce it is 40 robots instead of 30 ! LOL !
03/2015 1 for 500 reverse split !
Market
Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEOFont size: A | A | A
5:00 PM ET 7/20/17 | Dow Jones
CHARLESTON, S.C.--(BUSINESS WIRE)--July 20, 2017--
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), announced today that it has formed a special committee of independent directors (the "Strategic Review Committee") to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing business plan and/or considering and recommending changes to the Company's management and governance. The Strategic Review Committee will be chaired by Carolyn Egbert, and includes Michael Cardiff. The Strategic Review Committee is in the course of engaging a financial advisor to assist with this process. On July 18, the Company announced that it has been notified by the U.S. Food and Drug Administration ("FDA"), that the Company's New Drug Application ("NDA") seeking approval of Macrilen(TM) (macimorelin) for the evaluation of growth hormone deficiency in adults ("AGHD") has been accepted as a complete response to the FDA's November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017. The Company has reached an important point in its evolution and wishes to conduct a strategic review of its plans, resources and opportunities, in order to best position itself to maximize stakeholder value.
David A. Dodd has ceased to be the Company's President and CEO with immediate effect. The board of directors of the Company (the "Board") has appointed Michael Ward as the Company's Chief Executive Officer.
Mr. Ward has over thirty years of executive and legal experience in the healthcare, pharmaceutical and technology industries. Most recently, Mr. Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals (NASDAQ:SGNT), a global specialty generic pharmaceutical company, and led its sale to Nichi-Iko Pharmaceutical Co., Ltd. for $736 million. Mr. Ward has served as Strategic Advisor to Benevolent Capital Partners for the last five years and is currently a Partner with Outside GC LLC. Prior to Sagent Pharmaceuticals, Mr. Ward was Vice President, Assistant General Counsel of Global Compliance, Ethics & Litigation and Chief Privacy Officer at CDK Global. Mr. Ward has served in several executive roles and was responsible for business development, compliance, legal and operational matters in the healthcare, pharmaceutical and technology industries during his career. Mr. Ward graduated from Albion College and Case Western Reserve University Law School.
There can be no assurance that evaluation of strategic alternatives will result in any transaction being pursued, entered into or consummated. The Company does not intend to make further comment in regard to this process except as required by applicable securities laws or the policies of NASDAQ and the Toronto Stock Exchange.
Advisors
The Strategic Review Committee has engaged Bennett Jones LLP as its legal advisor and Bayfield Strategy, Inc. as its strategic and communications advisor.
About Macrilen(TM) (macimorelin)
Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone. Macimorelin has been granted orphan drug designation by the FDA for diagnosis of AGHD. The Company owns the worldwide rights to this patented compound and has significant patent protection left. The Company's U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. The Company proposes, subject to FDA approval, to market macimorelin under the tradename Macrilen(TM).
About AGHD
AGHD affects approximately 75,000 adults across the U.S., Canada and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words "expects, " "believes," "intends," "anticipates," and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known risks and uncertainties, many of which are discussed under the caption "Key Information -- Risk Factors" in our most recent Annual Report on Form 20-F filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission ("SEC"). Such statements include, but are not limited to, statements about the progress of our research, development and clinical trials and the timing of, and prospects for, regulatory approval and commercialization of our product candidates, the timing of expected results of our studies, anticipated results of these studies, statements about the status of our efforts to establish a commercial operation and to obtain the right to promote or sell products that we did not develop and estimates regarding our capital requirements and our needs for, and our ability to obtain, additional financing. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue our research and development projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the rejection or non-acceptance of any new drug application by one or more regulatory authorities and, more generally, uncertainties related to the regulatory process (including whether or not the regulatory authorities will definitively accept the Company's conclusions regarding Macrilen(TM) and approve its registration following the Company's re-submission of an NDA for the product as described elsewhere in this press release), the ability of the Company to efficiently commercialize one or more of its products or product candidates, the degree of market acceptance once our products are approved for commercialization, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, and the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian securities commissions and the SEC for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170720006325/en/
CONTACT: Bayfield Strategy, Inc.
1-844-226-3222 (North American Toll Free Number)
1-416-855-0238 (Outside North America)
info@bayfieldstrategy.com
SOURCE: Aeterna Zentaris Inc.
Copyright Business Wire 2017
> Dow Jones Newswires
Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEOFont size: A | A | A
5:00 PM ET 7/20/17 | Dow Jones
CHARLESTON, S.C.--(BUSINESS WIRE)--July 20, 2017--
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), announced today that it has formed a special committee of independent directors (the "Strategic Review Committee") to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing business plan and/or considering and recommending changes to the Company's management and governance. The Strategic Review Committee will be chaired by Carolyn Egbert, and includes Michael Cardiff. The Strategic Review Committee is in the course of engaging a financial advisor to assist with this process. On July 18, the Company announced that it has been notified by the U.S. Food and Drug Administration ("FDA"), that the Company's New Drug Application ("NDA") seeking approval of Macrilen(TM) (macimorelin) for the evaluation of growth hormone deficiency in adults ("AGHD") has been accepted as a complete response to the FDA's November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017. The Company has reached an important point in its evolution and wishes to conduct a strategic review of its plans, resources and opportunities, in order to best position itself to maximize stakeholder value.
David A. Dodd has ceased to be the Company's President and CEO with immediate effect. The board of directors of the Company (the "Board") has appointed Michael Ward as the Company's Chief Executive Officer.
Mr. Ward has over thirty years of executive and legal experience in the healthcare, pharmaceutical and technology industries. Most recently, Mr. Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals (NASDAQ:SGNT), a global specialty generic pharmaceutical company, and led its sale to Nichi-Iko Pharmaceutical Co., Ltd. for $736 million. Mr. Ward has served as Strategic Advisor to Benevolent Capital Partners for the last five years and is currently a Partner with Outside GC LLC. Prior to Sagent Pharmaceuticals, Mr. Ward was Vice President, Assistant General Counsel of Global Compliance, Ethics & Litigation and Chief Privacy Officer at CDK Global. Mr. Ward has served in several executive roles and was responsible for business development, compliance, legal and operational matters in the healthcare, pharmaceutical and technology industries during his career. Mr. Ward graduated from Albion College and Case Western Reserve University Law School.
There can be no assurance that evaluation of strategic alternatives will result in any transaction being pursued, entered into or consummated. The Company does not intend to make further comment in regard to this process except as required by applicable securities laws or the policies of NASDAQ and the Toronto Stock Exchange.
Advisors
The Strategic Review Committee has engaged Bennett Jones LLP as its legal advisor and Bayfield Strategy, Inc. as its strategic and communications advisor.
About Macrilen(TM) (macimorelin)
Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone. Macimorelin has been granted orphan drug designation by the FDA for diagnosis of AGHD. The Company owns the worldwide rights to this patented compound and has significant patent protection left. The Company's U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. The Company proposes, subject to FDA approval, to market macimorelin under the tradename Macrilen(TM).
About AGHD
AGHD affects approximately 75,000 adults across the U.S., Canada and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words "expects, " "believes," "intends," "anticipates," and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known risks and uncertainties, many of which are discussed under the caption "Key Information -- Risk Factors" in our most recent Annual Report on Form 20-F filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission ("SEC"). Such statements include, but are not limited to, statements about the progress of our research, development and clinical trials and the timing of, and prospects for, regulatory approval and commercialization of our product candidates, the timing of expected results of our studies, anticipated results of these studies, statements about the status of our efforts to establish a commercial operation and to obtain the right to promote or sell products that we did not develop and estimates regarding our capital requirements and our needs for, and our ability to obtain, additional financing. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue our research and development projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the rejection or non-acceptance of any new drug application by one or more regulatory authorities and, more generally, uncertainties related to the regulatory process (including whether or not the regulatory authorities will definitively accept the Company's conclusions regarding Macrilen(TM) and approve its registration following the Company's re-submission of an NDA for the product as described elsewhere in this press release), the ability of the Company to efficiently commercialize one or more of its products or product candidates, the degree of market acceptance once our products are approved for commercialization, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, and the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian securities commissions and the SEC for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170720006325/en/
CONTACT: Bayfield Strategy, Inc.
1-844-226-3222 (North American Toll Free Number)
1-416-855-0238 (Outside North America)
info@bayfieldstrategy.com
SOURCE: Aeterna Zentaris Inc.
Aeterna Zentaris names new CEO, forms special committee to consider and evaluate various strategic and financing alternatives Font size: A | A | A
5:17 PM ET 7/20/17 | Briefing.com
The co announced today that it has formed a special committee of independent directors to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing business plan and/or considering and recommending changes to the Company's management and governance. The Strategic Review Committee will be chaired by Carolyn Egbert, and includes Michael Cardiff. The Strategic Review Committee is in the course of engaging a financial advisor to assist with this process. The Company has reached an important point in its evolution and wishes to conduct a strategic review of its plans, resources and opportunities, in order to best position itself to maximize stakeholder value.
David A. Dodd has ceased to be the Company's President and CEO with immediate effect. The board of directors of the Company has appointed Michael Ward as the Company's Chief Executive Officer. Most recently, Mr. Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals, a global specialty generic pharmaceutical company, and led its sale to Nichi-Iko Pharmaceutical Co., Ltd. for $736 million
Aeterna Zentaris names new CEO, forms special committee to consider and evaluate various strategic and financing alternatives
http://ir.sunshineheart.com/ HOLDING THIS FOR AT LEAST A YEAR OR MORE
Stock was overbought on the FDA and now will start to regain as time moves on and filling comes into play! This stock has 2 analysts 1 at $3.35 and the other at $6.25 both just waiting for news such as earnings on 8/3 and Stanford study to be completed. This is a value play here and worry should not be in your cards !
Educate yourself on this great company ! http://ir.sunshineheart.com
Love the look of the chart after 12:30 ! Bears are out of here and Wednesday should be good!
Way oversold RSI !
DOES NOT READ WELL FOR US ! The FDA Oncology Drugs Advisory Committee Meeting held today (May 2nd, 2013) to review the NDA submitted by Delcath Systems (DCTH) resulting in 16-0 vote against the Melblez Kit in terms of demonstrated benefits versus potential risks given the clinical trial materials included in briefing materials released on April 30th 2013. The Melblez Kit, which was formerly known as CHEMOSAT, is a hybrid drug-device product that utilizes percutaneous hepatic perfusion (PHP) to deliver high doses of a chemotherapeutic agent directly to the liver. The product is designed to reduce the unwanted side effects of chemotherapy as a result of introduction of toxic agents into the rest of patients’ bodies while maximizing the efficiency of a chemotherapeutic regimen to patients’ livers. Specifically, the company chose Mephalan (aka Alkeran) as its chemotherapeutic agent. From the briefing documents: “Melphalan was selected as the chemotherapeutic agent for PHP treatment because it binds melanin precursors, is an alkylating agent with a steep dose response [Teicher et al, 1988], and has been used successfully in an analogous regional procedure, IHP, for treating unresectable hepatic metastases from melanoma” Trading was halted just before 1:00 PM EST for shares of DCTH. As initially mentioned on the update on Catalyst~Watch update on April 30th, the market had already reduced the valuation of Delcath significantly after the release of the FDA briefing documents. DCTH is already down ~47% since Monday’s open, although the extremely negative vote on the Melblez NDA is likely to bring the stock even lower. The PDUFA goal date for Melblez isn’t until September 13th 2013. While the FDA is not required to follow the advice of the advisory panel, it is extremely likely that Delcath will receive a CRL based on the adverse events that were seen during the clinical development process. The proposed REMS that was submitted along with the Melblez NDA was also deemed insufficient to mitigate the risks of a commercial launch of the Melblez Kit. These risks are outlined with results from Phase I studies:
Yes , I see what you mean but the company is still cheap !
SHORTING WITH NEWS ON THE HORIZON = FINANCIAL SUICIDE !